Drugs / Recombinant von Willebrand Factor
Recombinant von Willebrand Factor
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06118372 | Oct 2024 → Dec 2026 expected | blood coagulation disease | University of Virginia | Recruiting | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT02283268 | Apr 2015 → Jul 2016 | hereditary von Willebrand disease | Baxalta now part of Shire | Completed | No outcome recorded |
| Phase 3 | NCT01410227 | Nov 2011 → Feb 2014 | hereditary von Willebrand disease | Baxalta now part of Shire | Completed | No outcome recorded |
Also used as a comparator or background therapy in 2 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04344860 Comparator | Jun 2021 → Aug 2024 | von Willebrand disease (hereditary or acquired) | Nicoletta C Machin | Completed | No outcome recorded |
| Phase 3 | NCT02606045 Comparator | Feb 2019 → Apr 2022 | von Willebrand disease (hereditary or acquired) | Margaret Ragni | Terminated | No outcome recorded |
Press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2018-09-12 | Takeda | Shire granted EU marketing authorization for VEYVONDI® [vonicog alfa, recombinant von Willebrand factor] for adults with von Willebrand disease takeda.com ↗ |
| 2018-07-02 | Takeda | CHMP recommends EU marketing authorization for VEYVONDI® [vonicog alfa, recombinant von Willebrand factor] for adults with von Willebrand disease takeda.com ↗ |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | recombinant von Willebrand factor | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02606045 ↗ |
| Known as | recombinant vWF | “The primary objectives are to evaluate the safety, tolerability, and pharmacokinetics of recombinant vWF in adult ECMO patients.” NCT06118372 ↗ |
| Known as | rVWF | “Recombinant von Willebrand Factor (rVWF)” NCT02283268 ↗1“rVWF” NCT01410227 ↗ |
| Action | Restore | “peri- and postoperative substitution regimen” NCT02283268 ↗ |
| Modality | Protein / enzyme biologic | “a recombinant von Willebrand factor (rVWF)” PMID 26239086 ↗ Aug 2015 |
| Route | Intravenous | “rVWF will be administered by intravenous bolus infusion” NCT02283268 ↗ |